Oryzon Genomics Valuation
| ORY Stock | EUR 1.56 0.01 0.64% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Oryzon Genomics SA holds a recent Real Value of €1.65 per share. The prevailing price of the company is €1.56. Our model determines the value of Oryzon Genomics SA from analyzing the company fundamentals such as Operating Margin of (0.72) %, return on equity of -0.0685, and Shares Outstanding of 55.56 M as well as examining its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Oryzon Genomics' price fluctuation is relatively risky at this time. Calculation of the real value of Oryzon Genomics SA is based on 3 months time horizon. Increasing Oryzon Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Oryzon Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Oryzon Stock. However, Oryzon Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.56 | Real 1.65 | Hype 1.56 | Naive 1.59 |
The real value of Oryzon Stock, also known as its intrinsic value, is the underlying worth of Oryzon Genomics SA Company, which is reflected in its stock price. It is based on Oryzon Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Oryzon Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Oryzon Genomics SA helps investors to forecast how Oryzon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Oryzon Genomics more accurately as focusing exclusively on Oryzon Genomics' fundamentals will not take into account other important factors: Oryzon Genomics Total Value Analysis
Oryzon Genomics SA is now anticipated to have takeover price of 107.12 M with market capitalization of 140.29 M, debt of 10.35 M, and cash on hands of 29.11 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Oryzon Genomics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
107.12 M | 140.29 M | 10.35 M | 29.11 M |
Oryzon Genomics Asset Utilization
One of the ways to look at asset utilization of Oryzon is to check how much profit was generated for every dollar of assets it reports. Oryzon Genomics holds a negative application of assets of -0.0419 pct., losing €4.19E-4 for each euro of assets held by the company. Inadequate asset utilization implies the company is being less effective with each euro of assets it holds. Put it differently, asset utilization of Oryzon Genomics SA shows how discouraging it operates for each euro spent on its assets.Oryzon Genomics Ownership Allocation
Oryzon Genomics owns a total of 55.56 Million outstanding shares. Oryzon Genomics holds 18.04 pct. of its outstanding shares held by insiders and 0.72 pct. owned by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Oryzon Genomics Profitability Analysis
Net Loss for the year was (4.69 M) with profit before overhead, payroll, taxes, and interest of 9.87 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Oryzon Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Oryzon Genomics and how it compares across the competition.
About Oryzon Genomics Valuation
The stock valuation mechanism determines Oryzon Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Oryzon Genomics. We calculate exposure to Oryzon Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Oryzon Genomics's related companies.Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people.
8 Steps to conduct Oryzon Genomics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Oryzon Genomics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Oryzon Genomics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Oryzon Genomics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Oryzon Genomics' revenue streams: Identify Oryzon Genomics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Oryzon Genomics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Oryzon Genomics' growth potential: Evaluate Oryzon Genomics' management, business model, and growth potential.
- Determine Oryzon Genomics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Oryzon Genomics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Oryzon Stock analysis
When running Oryzon Genomics' price analysis, check to measure Oryzon Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oryzon Genomics is operating at the current time. Most of Oryzon Genomics' value examination focuses on studying past and present price action to predict the probability of Oryzon Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oryzon Genomics' price. Additionally, you may evaluate how the addition of Oryzon Genomics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |